ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Pioneering examples of molecularly driven treatment are the development of tamoxifen in the seventies to target the oestrogen receptor in breast cancer and the kinase inhibitor imatinib for the treatment of chronic myelogenous leukaemia (CML) carrying the BCL-ABL1 chromosomal translocation [7,8].